Michael Leapman

2.9k total citations · 1 hit paper
186 papers, 1.6k citations indexed

About

Michael Leapman is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Michael Leapman has authored 186 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Pulmonary and Respiratory Medicine, 34 papers in Surgery and 34 papers in Oncology. Recurrent topics in Michael Leapman's work include Prostate Cancer Diagnosis and Treatment (83 papers), Prostate Cancer Treatment and Research (70 papers) and Economic and Financial Impacts of Cancer (19 papers). Michael Leapman is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (83 papers), Prostate Cancer Treatment and Research (70 papers) and Economic and Financial Impacts of Cancer (19 papers). Michael Leapman collaborates with scholars based in United States, Austria and Poland. Michael Leapman's co-authors include Matthew R. Cooperberg, Cary P. Gross, Preston Sprenkle, Jamil Syed, Kevin A. Nguyen, Paweł Rajwa, Jonathan Brajtbord, Walter Hsiang, Xiaomei Ma and Peter R. Carroll and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Michael Leapman

162 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Magnetic Resonance Imaging in Prostate Cancer Screening

2024 34 citations Tamás Fazekas, Michaël Baboudjian et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Leapman United States	23	916	296	263	193	167	186	1.6k
Florian R. Schroeck United States	23	915 1.0×	348 1.2×	596 2.3×	103 0.5×	244 1.5×	92	1.7k
Scott C. Flanders United States	21	1.4k 1.5×	502 1.7×	337 1.3×	132 0.7×	244 1.5×	68	1.9k
Mia Djulbegovic United States	10	740 0.8×	546 1.8×	163 0.6×	85 0.4×	94 0.6×	21	1.5k
Timothy J. Daskivich United States	26	961 1.0×	499 1.7×	559 2.1×	149 0.8×	73 0.4×	97	2.0k
Sanoj Punnen United States	22	1.0k 1.1×	307 1.0×	451 1.7×	242 1.3×	223 1.3×	98	1.8k
Katharina Böehm Germany	20	920 1.0×	276 0.9×	300 1.1×	167 0.9×	170 1.0×	111	1.5k
Thenappan Chandrasekar United States	22	1.0k 1.1×	407 1.4×	306 1.2×	198 1.0×	113 0.7×	130	1.7k
Paul Martin Putora Switzerland	22	907 1.0×	445 1.5×	237 0.9×	303 1.6×	65 0.4×	110	1.6k
Per Fransson Sweden	19	1.8k 2.0×	607 2.1×	423 1.6×	366 1.9×	157 0.9×	80	2.4k
Heather Payne United Kingdom	28	1.7k 1.8×	766 2.6×	450 1.7×	400 2.1×	186 1.1×	158	2.8k

Countries citing papers authored by Michael Leapman

Since Specialization

Citations

This map shows the geographic impact of Michael Leapman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Leapman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Leapman more than expected).

Fields of papers citing papers by Michael Leapman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Leapman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Leapman. The network helps show where Michael Leapman may publish in the future.

Co-authorship network of co-authors of Michael Leapman

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Leapman. A scholar is included among the top collaborators of Michael Leapman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Leapman. Michael Leapman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Miszczyk, Marcin, Giulio Francolini, Tamás Fazekas, et al.. (2025). Perirectal spacers in radiotherapy for prostate cancer – a systematic review and meta-analysis. Współczesna Onkologia. 29(1). 36–44.

Melnick, Kevin, Jihoon Chang, Madhur Nayan, et al.. (2025). Impact of tobacco use on postoperative complications following partial nephrectomy. Urologic Oncology Seminars and Original Investigations. 43(6). 395.e13–395.e21.

Soulos, Pamela R., Madhav KC, Molly M. Jeffery, et al.. (2025). Opioid prescribing trends and pain scores among adult patients with cancer in a large health system. Cancer. 131(19). e70027–e70027. 1 indexed citations

Long, Jessica B., Madhav KC, Terry Hyslop, et al.. (2025). Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer. JNCI Journal of the National Cancer Institute. 118(1). 130–140.

Long, Jessica B., Terry Hyslop, Andrea Silber, et al.. (2025). Risk of Late-Onset Depression in Long-Term Survivors of Breast, Prostate, and Colorectal Cancer. JAMA Network Open. 8(11). e2544812–e2544812.

Fazekas, Tamás, Maximilian Pallauf, Jakub Kufel, et al.. (2024). Molecular Correlates of Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: A Systematic Review. European Urology Oncology. 8(5). 1352–1364. 2 indexed citations

Justice, Amy C., Janet P. Tate, J. Michael Gaziano, et al.. (2024). Adaption and National Validation of a Tool for Predicting Mortality from Other Causes Among Men with Nonmetastatic Prostate Cancer. European Urology Oncology. 7(4). 923–932. 3 indexed citations

Rajwa, Paweł, et al.. (2024). Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. Urologic Oncology Seminars and Original Investigations. 43(1). 41–48. 9 indexed citations

Sundaresan, Vinaik, et al.. (2024). Sociodemographic disparities in prostate cancer imaging. Abdominal Radiology. 51(3). 1407–1415.

10.

Rahman, Syed N., Jessica B. Long, Michael Leapman, et al.. (2024). Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open. 7(4). e248747–e248747. 1 indexed citations

11.

Sundaresan, Vinaik, Soum D. Lokeshwar, Joseph Brito, et al.. (2024). Risk factors for Gleason score upgrade from prostate biopsy to radical prostatectomy. SHILAP Revista de lepidopterología. 5(5). 981–996. 2 indexed citations

12.

Lokeshwar, Soum D., et al.. (2024). Diagnostic utility of prostate health index density prior to MRI-ultrasound fusion targeted biopsy. Exploration of Targeted Anti-tumor Therapy. 5(6). 1168–1176. 1 indexed citations

13.

Hsiang, Walter, et al.. (2023). Access to urologic cancer care for Medicaid-insured patients. Urologic Oncology Seminars and Original Investigations. 41(4). 206.e21–206.e27. 2 indexed citations

14.

Hsiang, Walter, Michelle C. Salazar, Elizabeth R. Berger, et al.. (2023). Telehealth Availability for Cancer Care During the COVID-19 Pandemic: Cross-Sectional Study. JMIR Cancer. 9. e45518–e45518. 2 indexed citations

15.

Chu, Carissa, Michael Leapman, Shoujun Zhao, et al.. (2023). Prostate cancer disparities among American Indians and Alaskan Natives in the United States. JNCI Journal of the National Cancer Institute. 115(4). 413–420. 6 indexed citations

16.

Lokeshwar, Soum D., et al.. (2023). Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer. Current Urology Reports. 24(10). 455–461. 1 indexed citations

17.

Lokeshwar, Soum D., Syed N. Rahman, Richard Ho, et al.. (2022). Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer. Urologic Oncology Seminars and Original Investigations. 40(9). 407.e21–407.e27. 2 indexed citations

18.

Wilson, Lauren E., Bradford E. Jackson, Lisa P. Spees, et al.. (2022). End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. JCO Oncology Practice. 19(2). e213–e227. 1 indexed citations

19.

Spees, Lisa P., Stephanie B. Wheeler, Bradford E. Jackson, et al.. (2021). Provider‐ and patient‐level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Cancer Medicine. 10(19). 6653–6665. 3 indexed citations

20.

Nabavizadeh, Behnam, et al.. (2021). Characteristics of Online Crowdfunding Campaigns for Urological Cancers in the United States. Urology Practice. 9(1). 56–63. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact